Searchable abstracts of presentations at key conferences in endocrinology

ea0015p311 | Steroids | SFEBES2008

Testosterone increases kidney weight in orchiectomized male Wistar rats but not dihydrotestosterone

Michaelis Marten , Hofmann Peter , Rohde Wolfgang , Goetze Franziska , Quinkler Marcus

Introduction: Androgens are known to play an important role in renal tubular epithelial cell growth, hypertrophy and erythropoetin production, however the exact mechanisms are not clear yet. 5α-dihydrotestosterone is synthesized primarily in gonads and skin, and is the most used androgen in studies. However, little is known about testosterone effects in non-gonadal tissues.Methods: Male Wistar rats aged 8–10 weeks were orchiectomized and put on...

ea0013p51 | Clinical practice/governance and case reports | SFEBES2007

Medical treatment in adrenal insufficiency: Does the patient’s quality of life differ depending on which glucocorticoid is given?

Bleicken Benjamin , Ventz Manfred , Strasburger Christian J , Quinkler Marcus

Objective: Patients from FRG and West-Berlin with primary (1AI) or secondary (2AI) adrenal insufficiency were treated with hydrocortisone (HC) while in contrast patients from the former GDR received prednisolone (PR). Investigation of our study is to detect any differences in quality of life (QoL) in patients on HC or PR medication.Methods: 350 patients of our outpatient clinic were contacted by mail. Up to now 131 patients took part in the survey. 2 sta...

ea0049gp11 | Adrenal 2 | ECE2017

A country comparison of glucocorticoid replacement therapy in patients with primary and secondary adrenal insufficiency: data from the EU-AIR

Ekman Bertil , Quinkler Marcus , Zhang Pinggao , Zelissen Pierre , Murray Robert D.

Introduction: The daily maintenance dose of conventional hydrocortisone currently recommended by international guidelines for the management of primary adrenal insufficiency (PAI) or secondary adrenal insufficiency (SAI) is 15−25 mg/day, in 2−3 divided doses. The aim of this analysis was to investigate inter-country differences in glucocorticoid replacement doses in patients with PAI and SAI.Design: EU-AIR (ClinicalTrials.gov identifier: NCT0...

ea0049gp20 | Adrenal 2 | ECE2017

Which are the factors and causes of death in patients with adrenal insufficiency? Mortality data from EU-AIR

Quinkler Marcus , Ekman Bertil , Zhang Pinggao , Zelissen Pierre , Murray Robert D

Introduction: If untreated, adrenal insufficiency (AI) leads to premature death. Hospital record data suggest mortality associated with primary (PAI) and secondary AI (SAI) to be 2–3-fold higher than in the general population. Major causes of death include cardiovascular disease, Addisonian crises, brain tumours and infections; however, there is little further characterization of patients who died.Design: We analysed real-world data from the Europea...

ea0049ep22 | Adrenal cortex (to include Cushing's) | ECE2017

Cardiovascular risk factors do not play a role in the risk factor profile of adrenal crisis

Quinkler Marcus , Murray Robert D. , Zhang Pinggao , Zelissen Pierre , Ekman Bertil

Introduction: Adrenal crises (ACs) are life-threatening events in patients with primary (PAI) or secondary (SAI) adrenal insufficiency, occurring ~4–10 times per 100 patient-years. Major causes of ACs are infections, especially gastroenteritis and tonsillitis/laryngitis. Risk factors for ACs remain ill defined, but could include concomitant endocrine diseases (diabetes mellitus, premature ovarian failure) in PAI, diabetes insipidus in SAI, and concomitant non-endocrine di...

ea0041oc1.3 | Adrenal - Basic & Clinical | ECE2016

Hormone replacement therapy with prednisolone is associated with a worse lipid profile than replacement with hydrocortisone in patients with adrenal insufficiency: a matched analysis of data from the EU-AIR

Quinkler Marcus , Ekman Bertil , Marelli Claudio , Uddin Sharif , Zelissen Pierre , Murray Robert

Introduction: Prednisolone is the standard treatment for most inflammatory conditions. However, it is also used in hormone replacement therapy in adrenal insufficiency (AI) for historical reasons or due to its longer half-life and once-daily application. Recent data indicate that daily prednisolone could be associated with lower bone mineral density than daily hydrocortisone in patients with AI. However, data on risk factors for cardiovascular disease in patients with AI treat...

ea0038p410 | Steroids | SFEBES2015

Hormone replacement therapy with prednisolone in adrenal insufficiency patients: data from the European Adrenal Insufficiency Registry (EuAIR)

Quinkler Marcus , Ekman Bertil , Marelli Claudio , Uddin Sharif , Zelissen Pierre , Murray Robert

Introduction: Prednisolone is the standard treatment for most inflammatory conditions. However, it is also used in hormone replacement therapy in adrenal insufficiency (AI) due to historical reasons or due to its longer half-life and once daily application. Recent data showed that 5 mg daily prednisolone promotes loss in bone mineral density compared to 20 mg of hydrocortisone in patients with AI questioning the 4:1 conversion rate. Data is scarce on prednisolone treated AI pa...

ea0038p419 | Steroids | SFEBES2015

Heterogeneity in the clinical management of adrenal insufficiency – data from EU-AIR

Murray Robert , Ekman Bertil , Uddin Sharif , Marelli Claudio , Quinkler Marcus , Zelissen Pierre

Introduction: Glucocorticoid (GC) replacement therapy is administered to patients with adrenal insufficiency (AI) in multiple daily doses; however, there are no consensus guidelines on the optimal regimen.Methods: The European Adrenal Insufficiency Registry (EU-AIR) is a multinational, multicentre, observational study sponsored by Shire, initiated to monitor the long-term safety of GC replacement in patients with chronic AI. We analysed baseline data to ...

ea0037ep39 | Adrenal cortex | ECE2015

Clinical management of adrenal insufficiency shows significant heterogeneity: data from the EU-AIR study

Murray Robert D , Ekman Bertil , Jones Beverly A , Marelli Claudio , Quinkler Marcus , Zelissen Pierre

Introduction: No consensus guidelines currently exist as to the optimal glucocorticoid regimen in adrenal insufficiency (AI). In clinical practice physicians utilise a number of different glucocorticoids, usually administered in several doses throughout the day.Methods: The EU-AIR registry is a European multinational, multicentre, prospective, observational study sponsored by Shire inclusive of all patients with AI irrespective of aetiology. We analysed ...